NewEdge Advisors’s ADMA Biologics ADMA Stock Holding History

NewEdge Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195K	Buy	23,332 +23,087	+9,423%	+$210K	﹤0.01%	2782
2026 Q1	$2.21K	Buy	245 +11	+5%	+$174	﹤0.01%	3791
2025 Q4	$4.27K	Hold	234	–	–	﹤0.01%	3723
2025 Q3	$3.43K	Sell	234 -28,679	-99%	-$492K	﹤0.01%	3640
2025 Q2	$527K	Buy	28,913 +28,679	+12,256%	+$585K	﹤0.01%	1649
2025 Q1	$4.64K	Hold	234	–	–	﹤0.01%	3323
2024 Q4	$4.01K	Buy	+234	New	+$4.4K	﹤0.01%	3291

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NewEdge Advisors's ADMA Position: Q2 2026 in Review

NewEdge Advisors increased its ADMA Biologics (ADMA) stake by 9,423% in Q2 2026, buying an estimated $210K and bringing the position to 23,332 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

NewEdge Advisors first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $527K in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

NewEdge Advisors held 23,332 shares of ADMA Biologics worth $195K as of Q2 2026.
NewEdge Advisors bought 23,087 ADMA Biologics shares in Q2 2026, an estimated $210K.
ADMA Biologics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2782 holding.
NewEdge Advisors first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
NewEdge Advisors's ADMA Biologics position peaked at $527K in Q2 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.